Collectively, these results suggested a post-transcriptional regulation TRAIL-R2/DR5 expression by PIM kinases, confirming results obtained in GBM cells treated with PIM kinases inhibitor (Fig. 3C). The gene discussed is TNFRSF10B; the disease is glioblastoma.